Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan Herrmann

Showing results (271-280 of 470) with videos related to

Pageof 47
Sort By:
The Cochrane Database of Systematic Reviews|July 14, 2021
Mini-Cog for the detection of dementia within a community settingBruce A Fage, Calvin Ch Chan, Sudeep S Gill, et al.
Psychiatry Research|July 6, 2019
Symptoms of depression and cognitive impairment in young adults after stroke/transient ischemic attackArunima Kapoor, Courtney Scott, Krista L Lanctot, et al.
Journal of the American Medical Directors Association|February 21, 2012
Efficacy and feasibility of nonpharmacological interventions for neuropsychiatric symptoms of dementia in long term care: a systematic reviewDallas P Seitz, Sarah Brisbin, Nathan Herrmann, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|July 23, 2009
Factor analysis of the Rivermead Post-Concussion Symptoms Questionnaire in mild-to-moderate traumatic brain injury patientsNathan Herrmann, Mark J Rapoport, Ryan D Rajaram, et al.
The Journal of Clinical Psychiatry|September 12, 2013
Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trialPaul B Rosenberg, Krista L Lanctôt, Lea T Drye, et al.
Journal of Geriatric Psychiatry and Neurology|May 17, 2024
Neurofilament Light Chain as a Biomarker of Global Cognition in Individuals With Possible Vascular Mild Cognitive ImpairmentAmish Gaur, Damien Gallagher, Nathan Herrmann, et al.
International Psychogeriatrics|January 13, 2026
Assessment of clinical factors that predict response to nabilone for agitation in Alzheimer's disease: A post hoc analysis of a randomized placebo-controlled trialOriel J Feldman, Nathan Herrmann, Myuri Ruthirakuhan, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 11, 2017
Peripheral inflammatory markers in Alzheimer's disease: a systematic review and meta-analysis of 175 studiesKa Sing P Lai, Celina S Liu, Allison Rau, et al.
Journal of Alzheimer'S Disease : JAD|July 20, 2019
24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer's Disease: Analyses from a Clinical Trial with NabiloneMyuri Ruthirakuhan, Nathan Herrmann, Ana C Andreazza, et al.
Brain and Behavior|December 5, 2017
Plasma sphingolipids and depressive symptoms in coronary artery diseaseAdam Dinoff, Mahwesh Saleem, Nathan Herrmann, et al.
Pageof 47

Showing results (271-280 of 470) with videos related to

Sort By:
Pageof 47
The Cochrane Database of Systematic Reviews|July 14, 2021
Mini-Cog for the detection of dementia within a community settingBruce A Fage, Calvin Ch Chan, Sudeep S Gill, et al.
Psychiatry Research|July 6, 2019
Symptoms of depression and cognitive impairment in young adults after stroke/transient ischemic attackArunima Kapoor, Courtney Scott, Krista L Lanctot, et al.
Journal of the American Medical Directors Association|February 21, 2012
Efficacy and feasibility of nonpharmacological interventions for neuropsychiatric symptoms of dementia in long term care: a systematic reviewDallas P Seitz, Sarah Brisbin, Nathan Herrmann, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|July 23, 2009
Factor analysis of the Rivermead Post-Concussion Symptoms Questionnaire in mild-to-moderate traumatic brain injury patientsNathan Herrmann, Mark J Rapoport, Ryan D Rajaram, et al.
The Journal of Clinical Psychiatry|September 12, 2013
Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trialPaul B Rosenberg, Krista L Lanctôt, Lea T Drye, et al.
Journal of Geriatric Psychiatry and Neurology|May 17, 2024
Neurofilament Light Chain as a Biomarker of Global Cognition in Individuals With Possible Vascular Mild Cognitive ImpairmentAmish Gaur, Damien Gallagher, Nathan Herrmann, et al.
International Psychogeriatrics|January 13, 2026
Assessment of clinical factors that predict response to nabilone for agitation in Alzheimer's disease: A post hoc analysis of a randomized placebo-controlled trialOriel J Feldman, Nathan Herrmann, Myuri Ruthirakuhan, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 11, 2017
Peripheral inflammatory markers in Alzheimer's disease: a systematic review and meta-analysis of 175 studiesKa Sing P Lai, Celina S Liu, Allison Rau, et al.
Journal of Alzheimer'S Disease : JAD|July 20, 2019
24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer's Disease: Analyses from a Clinical Trial with NabiloneMyuri Ruthirakuhan, Nathan Herrmann, Ana C Andreazza, et al.
Brain and Behavior|December 5, 2017
Plasma sphingolipids and depressive symptoms in coronary artery diseaseAdam Dinoff, Mahwesh Saleem, Nathan Herrmann, et al.
Pageof 47